Please login to the form below

Not currently logged in

Eisai to transfer US manufacturing campus to Biogen

Willhand over Research Triangle Park facility incapacity-sharing deal


Eisai has transferred ownership of its North Carolina manufacturing campus to Biogen in an expansion of the capacity-sharing deal they signed in 2013.

The change will affect approximately 100 of Eisai's Research Triangle Park employees, who will be offered jobs with Biogen once the deal is complete, but Eisai's Baltimore manufacturing facility will not be affected.

Under the terms of their new agreement Biogen will continue to manufacture oral solid-dose products for Eisai and will now also produce the Japanese company's parenteral products.

Eisai will, however, retain a base in North Carolina, which will continue to be home to its global partnership management, quality assurance, supply chain and business support staff.

At present these functions are housed on the Research Triangle Park campus, where they will remain for the next six months until the company secures new offices for them.

Lou Arp, general manager of the Eisai RTP site and president of the Global Oncology Manufacturing Unit for Eisai Inc, said: "The decision to transfer ownership of the RTP campus is part of a global supply chain initiative to optimise Eisai's logistics strategy in support of our long-term business objectives.

"Eisai and Biogen have had a successful alliance for a number of years. We share a patient-centric culture and have compatible values on how we perform our work. This arrangement is a natural fit and complementary to both companies, ensuring the state-of-the-art RTP facility operates at a higher capacity and jobs stay in North Carolina."

The property ownership transfer includes all Eisai's buildings on the campus, with its parenteral facility to be transferred when the deal closes and the oral solid-dose facility follow after an existing short-term lease expires.

Article by
Dominic Tyer

21st July 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...